




# Meenakshi Jolly, MD, MS

The George W. Stuppy, MD, Chair of Arthritis

## Advancement of Medicine

Lupus is an autoimmune disease that predominantly affects young women. It is more common among people of color and is associated with worse health outcomes. I established the Rush Lupus Clinic and serve as its director. The clinic provides patients with comprehensive, leading-edge care. Our research focuses on health outcomes in patients with rheumatologic conditions like lupus, with an emphasis on patient-reported outcomes. We utilize the biopsychosocial model for health to better understand the disease and patients' roles in health outcomes. Our goal is to identify and increase our understanding of modifiable factors that may be used to optimize health outcomes for patients with lupus. At Rush University, we have developed patient-reported survey tools, LupusPRO and the Lupus Impact Tracker. We use these to provide patient care, educate patients and health care personnel, and conduct research. Medical trainees and fellows gain valuable experience providing expert care in the Rush Lupus Clinic.



## Research, Education and Leadership Highlights

- I serve as the site principal investigator for the **Lupus Clinical Trials Network** and am the principal investigator on several lupus-related trials.
- I served as the **abstract reviewer** for lupus for the American College of Rheumatology's national rheumatology conference.
- I was invited to serve on the expert panel for patient-reported outcomes by **the Lupus Accelerating Breakthroughs Consortium** through the Lupus Research Alliance. This effort aims to guide the U.S. Food and Drug Administration, pharmaceutical companies and scholarly researchers in this field to identify which patient-reported outcome tools should be integrated into future clinical trials.

- I continued to serve on the editorial board of the **peer-reviewed journal *Lupus*** and continue to review for other leading rheumatology journals.
- I was **invited to speak at several universities and academic conferences**, locally and within the U.S. These included the Lupus 21st Century Conference, the Lupus Accelerating Breakthroughs Consortium, the American College of Rheumatology's State-of-the-Art Clinical Symposium, and grand rounds at the National Institutes of Health, Ascension Health, Advocate Lutheran General Hospital, and Oregon Health & Science University.
- We published **three original research papers** in leading peer-reviewed journals — two in clinical areas (pertaining to an intervention study optimizing patient discharge instructions and the inadequacy and readability of patient educational materials available to patients with rheumatologic diseases) and one translational collaborative study (on CD11b suppression of TLR7-driven inflammatory responses in lupus nephritis).
- I **presented at the American College of Rheumatology** on the results of the Lupus Impact Tracker and LupusPRO from the AURORA clinical trial program in lupus nephritis. I also collaborated with Duke University on studies of pain and fatigue in lupus.
- I organized and spoke at **the Annual Lupus Educational Event at Rush** and spoke at “Lupus Love,” organized by the Lupus Society of Illinois.

### Publication Highlights

- Joseph D, Hu R, Min R, Jolly M, Hassan S. Use and Utility of Patient After-Visit Instructions at a University Rheumatology Outpatient Clinic: Status and Randomized Prospective Pilot Intervention Study. *ACR Open Rheumatology*. 2024 Feb 22
- Li X, Villanueva V, Jimenez V, Nguyen B, Chauhan NR, Khan SQ, Dorschner JM, Jensen MA, Alzahrani K, Wei H, Cimbaluk DJ, Wei DC, Jolly M, Lopez-Rodriguez D, Pineda SB, Barbosa A, Vazquez-Padron RI, Faridi HM, Reiser J, Niewold TB, Gupta V. CD11b suppresses TLR7-driven inflammatory signaling to protect against lupus nephritis. *bioRxiv*. 2024 Jul 26
- Rustomji Y, Nweke UC, Hassan S, Ahmad U, Jolly M. Not So Patient Friendly: Patient Education Materials in Rheumatology and Internal Medicine Fall Short of Nationally Recommended Readability Benchmarks in the United States. *Arthritis Care & Research* (Hoboken). 2025 May



- Jolly M, Truman M, Flauto R, Dao K. Validity, Reliability and Responsiveness of Lupus Impact Tracker and LupusPRO: AURORA Trial [abstract]. *Arthritis & Rheumatology*. 2024; 76 (suppl 9).
- Jolly M, Truman M, Flauto R, Dao K. Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO [abstract]. *Arthritis & Rheumatology*. 2024; 76 (suppl 9).
- Eudy A, Clowse M, Jolly M, Pisetsky D, Sun K, Sadun R, Criscione-Schreiber L, Maheswaranathan M, Doss J, Rogers J. Impact of Pain and Fatigue on Quality of Life Among Patients with Systemic Lupus Erythematosus [abstract]. *Arthritis & Rheumatology*. 2024; 76 (suppl 9).

### Ongoing Clinical Trials

- A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)
- An Open Label Multicenter Study to Assess the Relationship Between Data Obtained with the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients with Systemic Lupus Erythematosus (SLE)
- A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without BENLYSTA™ (belimumab). Human Genome Sciences, Inc/ GlaxoSmithKline, Protocol HGS1006-C1124

### The Year Ahead: 2025 and Beyond

Looking ahead, funds from this endowment will support dedicated time to establish a prospective lupus registry at Rush to collect data on health outcomes. This will serve as the foundation for several projects related to pain, fatigue and cognition in patients with lupus, and may benefit trainees interested in this field.



## **With Gratitude**

Thank you for your investment. It will greatly help me with my efforts in educational, clinical and research missions pertaining to lupus. This autoimmune disease preferentially impacts young women, impairing multiple dimensions of their daily lives.